de Baere, T.; Guiu, B.; Ronot, M.; Chevallier, P.; Sergent, G.; Tancredi, I.; Tselikas, L.; Dioguardi Burgio, M.; Raynaud, L.; Deschamps, F.;
et al. Real Life Prospective Evaluation of New Drug-Eluting Platform for Chemoembolization of Patients with Hepatocellular Carcinoma: PARIS Registry. Cancers 2020, 12, 3405.
https://doi.org/10.3390/cancers12113405
AMA Style
de Baere T, Guiu B, Ronot M, Chevallier P, Sergent G, Tancredi I, Tselikas L, Dioguardi Burgio M, Raynaud L, Deschamps F,
et al. Real Life Prospective Evaluation of New Drug-Eluting Platform for Chemoembolization of Patients with Hepatocellular Carcinoma: PARIS Registry. Cancers. 2020; 12(11):3405.
https://doi.org/10.3390/cancers12113405
Chicago/Turabian Style
de Baere, Thierry, Boris Guiu, Maxime Ronot, Patrick Chevallier, Géraldine Sergent, Illario Tancredi, Lambros Tselikas, Marco Dioguardi Burgio, Lucas Raynaud, Frederic Deschamps,
and et al. 2020. "Real Life Prospective Evaluation of New Drug-Eluting Platform for Chemoembolization of Patients with Hepatocellular Carcinoma: PARIS Registry" Cancers 12, no. 11: 3405.
https://doi.org/10.3390/cancers12113405
APA Style
de Baere, T., Guiu, B., Ronot, M., Chevallier, P., Sergent, G., Tancredi, I., Tselikas, L., Dioguardi Burgio, M., Raynaud, L., Deschamps, F., & Verset, G.
(2020). Real Life Prospective Evaluation of New Drug-Eluting Platform for Chemoembolization of Patients with Hepatocellular Carcinoma: PARIS Registry. Cancers, 12(11), 3405.
https://doi.org/10.3390/cancers12113405
